Defining Aggressive Prostate Cancer Using a 12-Gene Model  by Bismar, Tarek A. et al.
Defining Aggressive Prostate Cancer Using a 12-Gene Model1
Tarek A. Bismar*,y,2, Francesca Demichelis*,y,z,§,2, Alberto Riva y,b, Robert Kim*, Sooryanarayana Varambally#,
Le He*, Jeff Kutok*,y, Jonathan C. Aster*,y, Jeffery Tang*,y, Rainer Kuefer**, Matthias D. Hofer*,y,
Phillip G. Febbo y,yy, Arul M. Chinnaiyan#,3 and Mark A. Rubin*,y,yy,3
*Department of Pathology, Brigham and Women’s Hospital, Boston, MA, USA; yHarvard Medical School, Boston,
MA, USA; zSRA Division, ITC-irst, Bioinformatics, Trent, Italy; §Department of Information and Communication
Technology, University of Trento, Trent, Italy; bChildren’s Hospital Informatics Program, Children’s Hospital,
Boston, MA, USA; #Department of Pathology and Urology, University of Michigan, Ann Arbor, MI, USA;
**University Hospital of Ulm, Ulm, Germany; yyDana Farber Cancer Institute, Boston, MA, USA
Abstract
The critical clinical question in prostate cancer re-
search is: How do we develop means of distinguish-
ing aggressive disease from indolent disease? Using a
combination of proteomic and expression array data,
we identified a set of 36 genes with concordant dys-
regulation of protein products that could be evaluated
in situ by quantitative immunohistochemistry. Another
five prostate cancer biomarkers were included using
linear discriminant analysis, we determined that the op-
timal model used to predict prostate cancer progres-
sion consisted of 12 proteins. Using a separate patient
population, transcriptional levels of the 12 genes en-
coding for these proteins predicted prostate-specific
antigen failure in 79men following surgery for clinically
localized prostate cancer (P = .0015). This study dem-
onstrates that cross-platform models can lead to pre-
dictive models with the possible advantage of being
more robust through this selection process.
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Introduction
Expression array technology has led to the development of
discrete molecular signatures. These signatures often in-
volve many genes that are able to characterize two or more
states, such as a model developed to identify aggressive,
diffuse, large B-cell lymphomas [1]. Various computational
strategies have been used to reduce these large lists of
genes to smaller nonredundant gene lists. A recent example
is a 70-gene prognostic panel predicting women at risk of
dying from breast cancer [2]. Another example is a 17-gene
signature of cancer metastasis [3]. Interestingly, several
solid tumors harboring this 17-gene signature were at a
significantly greater risk of disease progression. Other ex-
pression array studies examining prostate cancer progres-
sion have determined that as few as four to five genes could
identify men with a greater chance of prostate cancer pro-
gression [4,5]. Thus, compelling evidence exists, suggest-
ing that clinically relevant predictivemolecular models of cancer
progression are composed of less than 100 and more likely
significantly fewer genes after the removal of redundant genes
from the initial high-throughput screen.
Strategies to identify critical genes are emerging. Meta-
analysis of expression array studies has determined robust
candidate genes [6]. This approach identifies genes that are
differentially expressed regardless of the platform used for
discovery and represents one approach to sort through the
mounting expression array data being compiled [7]. This gen-
eral informatics approach to gene selection was recently vali-
dated in the classification of diffuse, large B-cell lymphomas by
demonstrating that, using genomewide expression array data,
one can boil down the principle components to six genes that
can predict clinical outcome [8].
In an attempt to further integrate various sources of molecu-
lar data with the goal of determining critical genes, we recently
combined data from a focused proteomics study and expres-
sion array analysis [9]. In this prior study, we interrogated over
1354 antibodies against distinct proteins or post-translational
modifications to interrogate tissue extracts derived from benign
prostate, clinically localized prostate cancer (LPCa), and meta-
static prostate cancer. More weight was given to genes that
were both overexpressed at the transcriptional level and simul-
taneously overexpressed at the protein level. Using integrative
analysis of this compendium of proteomic alterations and
transcriptome data derived from eight prostate cancer profiling
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studies, we observed only a 60% concordance between
protein and transcriptional levels. One important result was
identifying a subset of genes that predicted clinical outcome
based on this concordant overexpression at the mRNA and
protein levels. An intriguing observation from this initial study
was that a subset of 44 genes was sufficient to develop
models of cancer progression that are applicable not only to
prostate cancer but to other tumors as well. These models
could be tested by using expression array data sets that have
associated clinical outcome. One of the future goals of the
current approach should lead to the development of a clinical
tissue-based test that can be assessed in biopsy samples.
The current study therefore builds on this work by refining the
method of measuring the in situ expression of these proteins
using a prostate cancer progression tissuemicroarray (TMA).
Here, we present a molecular signature, composed of 12
genes, that characterizes prostate cancer progression.
Materials and Methods
Case Selection
As previously described, we have developed a prostate
cancer progression TMA to test biomarkers [10]. This TMA is
composed of benign prostate tissue (BEN), localized prostate
cancer, hormone-naı¨ve metastatic prostate cancer (META),
and hormone-refractory metastatic prostate cancer (WAP).
These cases came from well-fixed radical prostatectomy,
lymph node, and metastatic prostate cancer specimens from
the University of Michigan (Ann Arbor, MI), the University Hos-
pital of Ulm (Ulm, Germany), and the rapid autopsy program
[University of Michigan Specialized Program of Research
Excellence (SPORE)] for prostate cancer [11,12]. The meta-
static samples from the rapid autopsy program were all
histologically confirmed prostatic tumors involving solid organs
(e.g., liver and lung) or distant lymph nodes, as recently de-
scribed [11]. All samples were collected with prior Institutional
Review Board approval at each respective institution.
Selection of Biomarkers for Immunohistochemistry
The majority of biomarkers for this study were derived
from a large-scale proteomics study where more than
1354 proteins were screened [9]. Refinement of this list
of proteins included coordinate overexpression or under-
expression by cDNA expression array analysis [6,7,13,14].
The initial selection process identified 50 dysregulated pro-
teins, of which 36 were optimized for in situ tissue evaluation
by immunohistochemistry on archival formalin-fixed, paraffin-
embedded materials [9]. Five additional prostate cancer
biomarkers [Kruppel-like factor 6 (KLF6), Muc1, p63, Ki67,
and zinc alpha-2-glycoprotein (ZAG)] were included in
this multiplex model based on their association with can-
cer progression. Forty-one biomarkers are presented in
Table 1. This list includes prostate-specific antigen (PSA)
[15,16], alpha-methylacyl CoA racemase (AMACR) [17–21],
E-cadherin [22–26], p27 [27–31], fatty acid synthase (FAS)
[32–35], Mib1/Ki67 [36–38], and androgen receptor (AR)
[39]. This list also includes genes that have been more
recently associated with prostate cancer, such as E2F
[40–43], enhancer of Zeste 2 (EZH2) [13,44–46], Jagged
1 [47,48], metastasis-associated gene 1 (MTA1) [45,49], p63
[50–52], ZAG [53,54], MUC1 [53,55], and X-linked inhibitor
of apoptosis (XIAP) [56,57], which have also been recently
associated with prostate cancer progression; tumor pro-
tein D 52 (TPD52), a candidate oncogene identified in 8q21
amplicon, was recently identified to be associated with pros-
tate cancer progression and the development of hormone-
refractory prostate cancer [58–64]. The remaining genes,
such as ABP280 (Filamin A locus, FLNA), JAM1, BM28, and
FAS (a protein that had been known to be overexpressed in
prostate cancer and consistently seen to be overexpressed in
expression array studies), have not been specifically associ-
ated with prostate cancer progression [6,33,35].
Several of the markers selected for analysis, such as
E-cadherin [24,25,65] and XIAP [66], have been associated
with cancer outcome. We also included some other bio-
markers that have previously been reported to be associated
with prostate cancer but were not identified in the screening
study, such as KLF6, as this was reported to have a high level
of loss of heterozygosity and mutation in prostate cancer [67]
and was subsequently found to be one of five genes included
in a molecular signature of aggressive prostate cancer [5].
Quantitative Biomarker Analysis
Protein expression was evaluated by immunohistochem-
istry using a semiautomated quantitative image analysis
system ACIS II (Chromavision Medical Systems, Inc., San
Juan Capistrano, CA). ACIS II consists of a microscope with
a computer-controlled mechanical stage. Proprietary soft-
ware is used to detect the brown stain intensity of the
chromogen used for immunohistochemical analysis and to
compare this value to the intensity of the blue counterstain
used as background. Intensity levels are recorded as inten-
sity units ranging from 0 to 255. The reproducibility of the
ACIS II system was tested and confirmed by the scoring of
the same TMA on separate occasions (r 2 = 0.997; data not
shown). Given the heterogeneity of prostate tissue samples,
study pathologists used a computer-based selection tool
to highlight areas within each 0.6-mm core for analysis. To
account for this heterogeneity, we evaluated four tissue cores
for each case. In cases where less than three cores were
available, we substituted the datawith themedian value of the
biomarker for histologic subtype. Missing values can arise
both from corrupted core sections (i.e., technically inade-
quate) and from a change of diagnosis. Missing values were
present in the data set: 98 times in benign prostate (13.3%),
130 times in localized prostate cancer (17.6%), and 6 times in
metastatic prostate cancer samples (0.8%). The change of
histologic diagnosis was not a rare event; therefore, it sup-
ports the need to review all TMA cores. As a pooling strategy,
we adapted the mean TMA core value for each patient.
The diagnosis of the selected area was recorded in the
database as either benign prostate, localized prostate can-
cer, or metastatic prostate cancer. Cores with only stroma or
nondiagnostic areas were excluded from further analysis.
Hematoxylin and eosin–stained images from this tissue
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Clustering Separate hierarchical agglomerative clustering
both on samples and genes was carried out using Pearson cor-
relation (as similarity measure) and average linkage method
[68]. Clustering was performed using dChip software [69].
Linear discriminant analysis (LDA) LDAwas applied on the
data set of 41 genes to select genes [70,71] that can be
discriminated among diagnostics groups. Discriminant anal-
ysis uses both multivariate analysis of variance and discrim-
inant procedure to identify a linear combination of predictor
variables that best characterizes differences among the
groups. LDA computes so-called canonical variables (or ca-
nonical discriminant functions). The first canonical variable is
a linear combination of variables that maximizes the differ-
ences between the means of groups (one dimension). The
second canonical variable represents the maximum disper-
sion of the means in a direction that is orthogonal to the first
canonical variable. The other canonical variables are gener-
ated in a similar manner.
By applying a stepwise approach (adding and removing
variables on variance evaluation), the most powerful subset
of predicting variables can be defined. Stepwise selection
begins by identifying the variable for which the means are
most different and continues by stepwise addition of the next
best variable. Wilks’ lambda was used to control the entry or
removal of predictor variables from discriminant functions. In
discriminant analysis, prior probabilities were computed from
group sizes. LDA was performed using R [72] and SPSS
(SPSS, Inc., Chicago, IL).
Validation using expression array analysis Expression
data from a well-annotated, publicly available data set of
79 localized prostate tumors were obtained from Glinsky
et al. [5]. Features representing the 12 genes identified in
protein expression analysis were determined for U95Av2
Table 1. Data Description: Mean Values and 95% CIs for 41 Markers and 5 Groups.
BEN LPCa META WAP SM_CL
Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI
ABP280 0.65 0.69 0.42 1.02 1.61 0.71 0.63 1.46 0.57 0.02
AMACR 0.87 0.22 0.76 1.05 0.20 2.05 0.64 2.82 0.36 0.32
AR 0.33 1.77 0.37 1.57 0.40 1.97 0.44 2.14 1.73 1.09
BM28 0.63 0.44 0.11 1.41 0.07 2.98 0.54 1.90 2.27 1.64
BUB3 0.01 0.73 0.42 1.10 0.13 2.83 0.82 3.35 0.27 1.73
CaMKK 0.03 1.45 0.18 0.86 0.18 2.99 0.05 3.08 0.55 0.95
CASPASE3 1.00 0.89 0.30 1.15 0.17 1.94 1.35 0.84 1.03 0.68
CDK7 0.18 1.09 0.33 1.47 0.58 2.39 0.19 3.00 1.84 1.30
DYNAMIN 0.10 1.32 0.73 1.05 0.74 1.80 0.83 2.25 0.25 2.74
E2F-1 0.15 1.16 0.07 1.22 0.46 2.70 0.56 2.02 0.12 5.72
E-cadherin 0.03 1.33 0.31 1.48 0.66 2.00 0.64 2.13 2.42 1.93
EXPORTIN 0.02 1.25 0.24 1.44 0.18 2.41 0.21 3.96 0.40 0.95
EZH2 0.46 0.83 0.08 1.31 0.00 2.24 0.45 1.76 2.77 3.89
FAS 0.28 2.00 0.08 1.58 0.22 2.54 0.47 2.40 0.49 1.15
GAS7 0.20 1.54 0.09 1.49 0.05 2.27 0.24 2.83 0.12 3.13
GS28 0.18 0.84 0.28 0.91 0.34 0.53 1.00 4.36 0.53 2.19
ICBP90 0.42 0.98 0.58 1.86 0.47 2.30 0.46 1.23 1.95 2.58
ITGA5 0.15 1.14 0.18 1.25 1.34 1.31 0.31 1.42 0.40 0.43
Jagged 1 0.77 0.71 0.30 0.47 1.11 0.98 1.23 2.20 1.15 0.74
JAM1 0.03 1.16 0.06 0.85 1.24 2.43 0.75 1.37 1.56 3.48
KANADAPTIN 0.61 1.22 0.23 1.12 0.24 1.69 1.66 1.34 1.54 1.25
KLF6 0.09 1.41 0.05 1.24 0.62 2.66 1.11 2.60 0.02 2.50
KRIP1 0.35 1.43 0.33 1.58 0.02 1.66 0.15 1.90 1.57 6.30
LAP2 0.10 0.90 0.02 1.14 0.71 2.75 0.92 2.39 1.18 4.18
MCAM 0.40 0.86 0.05 1.50 0.93 2.72 0.16 2.38 1.32 1.42
MIB1 (MKi67) 0.49 0.11 0.17 0.52 0.36 0.44 1.21 3.31 3.05 0.79
MTA1 0.25 1.04 0.67 0.93 0.99 2.33 0.38 2.91 0.32 2.51
MUC1 0.33 0.26 0.30 1.28 0.24 0.87 1.16 3.21 2.75 0.71
Myosin VI 0.48 1.04 0.24 1.73 0.58 2.10 0.49 2.66 1.40 0.68
P27 0.62 1.42 0.20 1.78 0.26 2.05 1.30 1.06 0.04 0.11
P63 1.30 0.48 0.76 0.26 0.77 0.24 0.27 1.84 0.34 0.48
PAXILLIN 0.01 1.49 0.32 2.30 0.92 0.95 0.31 2.50 0.18 1.08
PLCLN 0.51 0.73 0.63 1.21 0.05 3.16 0.29 2.27 0.04 3.39
PSA (KLK3) 0.65 0.18 0.36 0.54 0.27 1.84 1.48 1.99 2.57 0.07
RAB27 0.79 0.50 0.30 1.44 0.95 1.78 1.16 0.64 1.62 0.27
RBBP 0.33 1.37 0.16 1.44 0.01 2.21 0.75 3.52 0.60 0.52
RIN1 1.00 0.54 0.35 1.36 1.16 0.51 1.13 0.46 1.11 0.25
SAPK alpha 0.05 1.18 0.05 0.99 0.09 2.78 0.22 3.14 1.36 2.75
TPD52 0.11 0.71 0.04 1.35 1.22 2.42 1.05 2.44 0.05 1.32
XIAP 0.43 1.28 0.74 1.02 0.90 1.58 0.58 2.35 1.63 0.04
ZAG 0.42 1.14 0.34 2.17 0.93 1.58 0.42 1.76 1.33 0.19
Key: BEN= benign prostate tissue; LPCA=clinically localized prostate cancer; META= hormone naı¨ve metastatic prostate cancer; WAP=hormone refractory
metastatic prostate cancer; SM_CL= small cell prostate cancer.
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microarrays and mapped to U133A microarrays using the
‘‘Best Match’’ table provided by Affymetrix (Santa Clara, CA).
Clustering was performed using the dChip software, as de-
scribed above [69]. Two major clusters determined using the
first branch point of the data set (C0 and C1) were identified,
and a chi-square test was performed to determine if the
distribution between C0 and C1 was nonrandom with respect
to clinical outcome (PSA failure versus nonfailure). These two
clusters (C0 vs C1), along with observed class (nonrecurrent
versus recurrent) and time to outcome (censorship or recur-
rence), were imported into GraphPad Prism to generate a
Kaplan-Meier plot and to calculate the log rank statistic.
Results
Selection of Genes for Analysis
Using a high-throughput proteomic screen of prostate
tissue extracts, we identified a panel of 50 proteins from
over 1354 that were differentially expressed [9]. In prior work,
this panel was evaluated by Western blot analysis, and the
candidate proteins that best distinguished between benign
prostate tissue, localized prostate cancer, and metastatic
prostate cancer were selected for further analysis. Further
selection required that these proteins were also concordantly
dysregulated at the transcriptome level, as previously de-
scribed [9]. We were able to optimize antibodies against 36
of these proteins that also worked on formalin-fixed paraffin-
embedded tissue samples. An additional five genes were
included based on prior association with prostate cancer
progression. Immunohistochemistry was then performed on
a prostate cancer progression TMA that has been previously
described and consists of BEN, LPCa, META, and WAP [10].
Immunohistochemical staining intensity was scored using an
automated image analysis system. The protein expression of
these genes, with mean staining intensity scores and 95%
confidence intervals (CIs), is presented in Table 1.
Hierarchical Clustering Results
We performed high-level analysis to check the data
quality present in the set of 41 selected proteins. In particular,
we investigated, through hierarchical clustering, if sufficient
protein expression data could distinguish different states of
prostate disease. Clustering was separately carried out on
the samples and the 41 proteins. The highest levels of the
sample tree (Figure 1A) demonstrated a good separation
Figure 1. Protein expression of 41 genes selected for differential expression in prostate cancer progression. (A) A ‘‘heat map’’ showing the relative protein
expression of 41 genes selected as highly likely to demonstrate differential expression in prostate tissue samples along the spectrum of cancer progression. Protein
expression was determined using antibodies directed against gene products and measured by immunohistochemistry and using a semiautomated image analysis
system (ACIS II; Chromavision Medical Systems, Inc.), which measures staining intensity along a continuous scale from 0 to 255. Low and high expressions are
depicted using light green and bright red, respectively. Hierarchical clustering of the samples demonstrates a good—but not perfect—ability of this 41-gene panel
to distinguish between classes. (B) Although some subtypes of metastatic prostate cancer (small cell cancer) (upper figure; original magnification, 200) had
discrete profiles, the clustering did not accurately distinguish between all of the hormone-naı¨ve and hormone-refractory prostate tumor samples. Interestingly, a
high-grade LPCa (Gleason pattern 4 prostate cancer) (lower figure; original magnification, 200) was found to cluster more closely to the metastatic samples using
this 41-gene profile.
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between aggressive prostate cancer states and LPCa. The
clustering also reliably distinguished BEN from LPCa. Al-
though metastatic tumors clustered together, no clear sub-
clusters were found for META and WAP, as demonstrated in
Figure 1A. Two cases of metastatic small cell prostate cancer
(SM_CL) clustered together (Figure 1B, top image). A sam-
ple of localized prostate cancer (LPCa_442-GL_7) was natu-
rally grouped with metastatic tumors. Although the overall
Gleason score for this case was 7, the sample analyzed for
this study (depicted in Figure 1B) demonstrated pure Glea-
son pattern 4 prostate cancer consistent with a high-grade
tumor. When clustering genes based on samples, it is no-
table that a group of seven genes (p63, ZAG, ABP280,
RAB27, RIN1, CASPASE3, and PSA) was overexpressed
in benign tissues and underexpressed in aggressive cancer.
Extreme overexpression and underexpression of these pro-
teins are present for aggressive cancer types (Figure 1, right
side), supporting the hypothesis that the investigated set of
markers might distinguish aggressive prostate cancer from
indolent prostate cancer. A heat map also suggests that
somegenes provide redundant or partially redundant informa-
tion, as confirmed by descriptive statistics presented in Table 1.
LDA
To verify the discriminative power of genes in terms of
cancer progression and to identify gene profiles specific for
localized prostate cancer and advanced prostate cancer, we
developed a predictive model based on protein expression.
LDA was applied to identify a linear combination of predictor
variables that best characterizes differences among the
groups. A clear separation of the groups was found, as de-
picted in Figure 2. The first and the second canonical vari-
ables cumulatively account for 91.7% of the variance (68.1%
and 23.6%, respectively). This result suggests that different
groups (benign, localized cancer, hormone-naı¨ve metasta-
ses, hormone-refractory metastases, and small cell cancer)
are linearly separable in gene space.
Stepwise LDA identified a set of 12 genes from the original
set of 41 studied genes that best predicted tumor progression
(Table 2) using 52 cases. Figure 2B represents the cases
along the first and the second canonical components, which
account for a cumulative variance of 87.9%. The discrimina-
tive power of the 12-gene model was not decreased with
respect to the 41-gene model, confirming also the redun-
dancy of information provided by some genes; alternative
subsets of genes from the 41-gene set could be selected.
Even though the model accuracy evaluated by crossvali-
dation (both using training and test sets 2/3 to 1/3 and
leave-one-out) was very good, reliable performances need
to be assessed on a different larger data set.
Expression Array Validation
The genes identified from the original proteomics screen
were selected because they demonstrated either over-
expression or underexpression at both the protein and tran-
scriptional levels [9]. In the current study, we have refined
this discriminatory panel to 12 genes. To determine if RNA
Figure 2. Stepwise LDA identified a group of 12 genes that best predicts prostate cancer progression (Table 2). (A) The heat map for these 12 genes. (B) Cases
along the first and the second canonical components of the LDA, which account for a cumulative variance of 87.9%. The discriminative power of the 12-gene model
was not decreased with respect to the 41-gene model, confirming also the redundancy of information provided by some genes.
Table 2. Stepwise LDA Data: Fisher Linear Discriminant Function Coef-
ficients (Classification Model).
Groups
BEN LPCa META WAP SM_CL
ABP280 (FLNA) 12.05 1.74 16.81 10.88 8.60
AMACR 3.18 3.80 10.10 1.78 14.03
CDK7 3.39 1.51 2.94 3.56 19.28
ITGA5 7.43 3.77 2.73 9.44 0.27
Jagged 1 10.04 1.60 11.47 11.76 13.77
KANADAPTIN 2.57 0.49 0.00 6.20 3.41
MIB1 (MKi67) 6.06 4.08 5.75 8.76 32.84
MTA1 2.18 2.32 8.73 0.02 3.26
MUC1 12.92 3.43 4.59 12.31 19.73
p63 41.51 10.06 24.94 31.61 49.72
PSA (KLK3) 11.82 2.26 7.45 14.78 38.07
TPD52 2.07 4.91 6.93 3.88 12.23
Constant 42.68 9.22 42.86 47.72 170.25
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expression of these 12 genes could discriminate between
local prostate cancers that progress following radical pros-
tatectomy from those that do not, a previously published data
set of 79 tumors was analyzed [5]. In an approach described
by Ramaswamy et al. [3], we used the dChip software to
develop a hierarchical cluster of all samples using features
representing the 12 genes included in our model or 15 fea-
tures on U133A (Figure 3A). When the 79 cases were clus-
tered using the dChip software, recurrent and nonrecurrent
samples were nonrandomly distributed between the two
major clusters (P < .01) (Figure 3A). When these major
clusters (C0 and C1) were used as a categorical variable
to divide the set for Kaplan-Meier analysis (Figure 3B), a sig-
nificant separation was observed between samples within
the two clusters with respect to PSA failure following sur-
gery (P = .0021). Thus, RNA expression of this group of
genes also appears to distinguish between localized tumors
that are likely to be aggressive from those that are cured
by surgery.
Discussion
Prostate cancer progression is a complex process involv-
ing many genes and pathways [73,74]. Although some
Figure 3. Expression array clustering of 79 clinical cases and Kaplan-Meier analysis. To validate if the expression of these 12 genes distinguishes men with more
aggressive prostate cancer, we employed an independent data set from a previously published study of 79 tumors analyzed at the Memorial Sloan Kettering
Cancer Center (New York, NY). (A) The first hierarchical clustering of the 79 samples, using the features representing the 12 genes included in our model (15
features on U133A), was performed. When the 79 cases were clustered using the dChip software, recurrent and nonrecurrent samples were nonrandomly
distributed between the two major clusters (P < .01). (B) When these major clusters (C0 and C1) were used as categorical variables to divide the set for Kaplan-
Meier analysis, a significant separation was observed between samples within the two clusters with respect to PSA failure following surgery (P = .0021). Thus, RNA
expression of this group of genes also appears to distinguish between localized tumors that are likely to be aggressive from those that are cured by surgery.
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alterations may be critical during early development (e.g., 8p
loss), more advanced metastatic prostate cancers demon-
strate numerousmolecular alterations thatmay not be causa-
tive but may instead be seen later during progression as a
consequence of genetic instability (e.g., PTEN mutations). It
is also evident from multiple expression array studies that
the genes identified to distinguish different disease states
(such as cancer versus benign) may differ. This may be due
to different molecular platforms, samples used for investiga-
tion, treatment effects, or analytic approaches used. One
approach used to develop a robust model has been the de-
termination of which genes are consistently differentially
regulated from experiment to experiment using a meta-
analysis of expression array data [6,7]. Using this approach,
we have focused on genes that were consistently dysre-
gulated both at the protein and expression array levels [9]
(Figure 4). This has now led to a focused model, including
12 genes from a starting point of over 1354 genes used in
the initial proteomics screening [9]. It is intriguing that this
12-gene model of prostate cancer progression, which was
initially developed using a TMA, was able to distinguish
men with LPCa who were at highest risk of developing PSA
failure following surgery. This testing and validation study
crossed platforms but was still able to predict outcomes on
an entirely independent clinical cohort.
Larger numbers of genes also might predict outcome.
However, as seen in the analysis of microarray studies, there
are many redundant genes. The reason for associated gene
expression patterns may be explained by the activation of
similar molecular pathways or general processes such as
proliferation or apoptosis. This observation supports the view
that one should, in fact, be surprised if all studies came up
with the same sets of genes. For example, in the current
study, after removing the 12-gene model from the original
41 genes, we can also identify good models from the re-
maining genes. Therefore, the approach used in this study
should be considered as a paradigm to identify predictive
gene sets, but should not be viewed as the only possible
solution. This study further supports the view that most of the
large molecular profiles have redundancy built into them.
Methods such as integrative proteomic and genomic analysis
demonstrate how critical it is to develop strategies to refine
large gene sets [9]. Other methods such as gene set enrich-
ment analysis [75–77] can also help define pathways of dys-
regulated genes, allowing us to focus on sets of genes or gene
interactions as opposed to lists of nonannotated genes.
Recent work from Glinsky et al. [78], which used a stem
cell– like expression profile selected by comparing two cell
lines, led to the identification of an 11-gene model. Unlike the
current study that used human tumor samples to identify and
refine genes for progression profiling, Glinsky et al. identified
their focused profile by comparing BMI-1–overexpressing
cells to a sister cell line that expresses BMI-1 at lower levels.
Previous work had demonstrated that BMI-1 plays a critical
role in the ability of stem cells to maintain self-renewal
[79,80]. Their novel signature was associated with poor
clinical outcome in 11 different types of cancer, including
prostate, breast, lung, ovarian, and bladder cancers. It is
Figure 4. The stages of biomarker development are presented schematically in this figure. The first critical step is the identification of high-quality samples used to
perform high-throughput analysis, including proteomics and expression array analysis. In this study, a wide range of prostate cancer samples was used from
several sources. Meta-analysis was performed to ensure that the genes identified in one study are genes that also have been determined to be dysregulated in
other studies. The data were then tested using TMAs, with the goal of developing a robust model. In the current study, a panel of 12 genes was determined. This
panel of genes was then validated on an independent data set to discriminate aggressive from indolent forms of prostate cancer. Throughout the entire process,
bioinformatics is required to prioritize and refine the molecular models.
Defining Aggressive Prostate Cancer Bismar et al. 65
Neoplasia . Vol. 8, No. 1, 2006
intriguing that the initial study of Varambally et al. [9] and
Glinsky et al. [78] using expression array profiles determined
a small set associated with poor clinical outcome. Our cur-
rent study focused on developing a tissue-based protein pro-
file, which also identified a small set of genes required to best
define prostate cancer progression.
In summary, we have developed a model of prostate
cancer progression that was developed using a multistage
approach. The first selection process sorted through over
1354 genes by evaluating a combination of cDNA expression
array analysis and a high-throughput proteomic screening,
which led to the identification of 50 differentially expressed
genes. The second stage described in the current study
tested a prostate cancer progression model using a quanti-
tative analysis of protein expression using immunohisto-
chemistry on a TMA. This led to a 12-gene model that was
validated on a separate patient cohort using PSA failure fol-
lowing surgery with LPCa as endpoint. This study demon-
strates that cross-platform models can lead to predictive
models. More importantly, this smaller model can be feasibly
used in a clinical setting. Future work will test this model in a
prospective manner.
Acknowledgements
The authors would like to thank Martina Storz-Schweizer and
Lela Schumacher for excellent technical support.
References
[1] Shipp M-A, Ross K-N, Tamayo P, Weng A-P, Kutok J-L, Aguiar R-CT,
Gaasenbeek M, Angelo M, Reich M, Pinkus G-S, et al. (2002). Diffuse
large B-cell lymphoma outcome prediction by gene-expression profiling
and supervised machine learning. Nat Med 8, 68–74.
[2] van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW,
Schreiber GJ, Peterse JL, Roberts C, Marton MJ, et al. (2002). A gene-
expression signature as a predictor of survival in breast cancer. N Engl
J Med 347, 1999–2009.
[3] Ramaswamy S, Ross KN, Lander ES, and Golub TR (2003). A molecular
signature of metastasis in primary solid tumors. Nat Genet 33, 49–54.
[4] Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo
P, Renshaw AA, D’Amico AV, Richie JP, et al. (2002). Gene expres-
sion correlates of clinical prostate cancer behavior. Cancer Cell 1,
203–209.
[5] Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, and Gerald WL
(2004). Gene expression profiling predicts clinical outcome of prostate
cancer. J Clin Invest 113, 913–923.
[6] Rhodes DR, Barrette TR, Rubin MA, Ghosh D, and Chinnaiyan AM
(2002). Meta-analysis of microarrays: interstudy validation of gene ex-
pression profiles reveals pathway dysregulation in prostate cancer.
Cancer Res 62, 4427–4433.
[7] Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D,
Barrette T, Pandey A, and Chinnaiyan AM (2004). ONCOMINE: A Can-
cer Microarray Database and Integrated Data-Mining Platform. Neopla-
sia 6, 1–6.
[8] Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R,
Botstein D, and Levy R (2004). Prediction of survival in diffuse large-
B-cell lymphoma based on the expression of six genes. N Engl J Med
350, 1828–1837.
[9] Varambally S, Yu J, LaxmanB,RhodesDR,MehraR, ShahRB, Chandran
U, Monzon FA, Becich MJ, Wei JT, et al. (2005). Integrative proteomic
and genomic analysis of prostate cancer progression. Cancer Cell 8(5),
393–406.
[10] Rubin MA, Zerkowski MP, Camp RL, Kuefer R, Hofer MD, Chinnaiyan
AM, and Rimm DL (2004). Quantitative determination of expression of
the prostate cancer protein alpha-methylacyl-CoA racemase using Au-
tomated Quantitative Analysis (AQUA): a novel paradigm for auto-
mated and continuous biomarker measurements. Am J Pathol 164,
831–840.
[11] ShahRB,Mehra R, Chinnaiyan AM, ShenR, GhoshD, ZhouM,Macvicar
S, Varambally S, Harwood J, Bismar TA, et al. (2004). Androgen-
independent prostate cancer is a heterogeneous group of diseases: les-
sons from a rapid autopsy program. Cancer Res 64, 9209–9216.
[12] Rubin MA, Putzi M, Mucci N, Smith DC, Wojno K, Korenchuk S, and
Pienta KJ (2000). Rapid (‘‘warm’’) autopsy study for procurement of
metastatic prostate cancer. Clin Cancer Res 6, 1038–1045.
[13] Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, and Rubin MA
(2003). Multiplex biomarker approach for determining risk of prostate-
specific antigen-defined recurrence of prostate cancer. J Natl Cancer
Inst 95, 661–668.
[14] Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D,
Barrette T, Pandey A, and Chinnaiyan AM (2004). Large-scale meta-
analysis of cancer microarray data identifies common transcriptional
profiles of neoplastic transformation and progression. Proc Natl Acad
Sci USA 101, 9309–9314.
[15] Stein BS, Vangore S, and Petersen RO (1984). Immunoperoxidase
localization of prostatic antigens. Comparison of primary and metastatic
sites. Urology 24, 146–152.
[16] Brawn PN, Speights VO, Kuhl D, Riggs M, Spiekerman AM, McCord
RG, Coffield KS, Stewart DT, and Lind ML (1991). Prostate-specific
antigen levels from completely sectioned, clinically benign, whole pros-
tates. Cancer 68, 1592–1599.
[17] Xu J, Stolk JA, Zhang X, Silva SJ, Houghton RL, Matsumura M, Vedvick
TS, Leslie KB, Badaro R, and Reed SG (2000). Identification of differ-
entially expressed genes in human prostate cancer using subtraction
and microarray. Cancer Res 60, 1677–1682.
[18] Jiang Z, Woda BA, Rock KL, Xu Y, Savas L, Khan A, Pihan G, Cai F,
Babcook JS, Rathanaswami P, et al. (2001). P504S: a new molecular
marker for the detection of prostate carcinoma. Am J Surg Pathol 25,
1397–1404.
[19] Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR,
Sanda MG, Pienta KJ, Ghosh D, and Chinnaiyan AM (2002). alpha-
Methylacyl coenzyme A racemase as a tissue biomarker for prostate
cancer. JAMA 287, 1662–1670.
[20] Luo J, Zha S, Gage WR, Dunn TA, Hicks JL, Bennett CJ, Ewing CM,
Platz EA, Ferdinandusse S, Wanders RJ, et al. (2002). alpha-Methyl-
acyl-CoA racemase: a new molecular marker for prostate cancer.
Cancer Res 62, 2220–2226.
[21] Kuefer R, Varambally S, Zhou M, Lucas PC, Loeffler M, Wolter H,
Mattfeldt T, Hautmann RE, Gschwend JE, Barrette TR, et al. (2002).
alpha-Methylacyl-CoA racemase: expression levels of this novel
cancer biomarker depend on tumor differentiation. Am J Pathol 161,
841–848.
[22] Bussemakers MJ, van Moorselaar RJ, Giroldi LA, Ichikawa T, Isaacs JT,
Takeichi M, Debruyne FM, and Schalken JA (1992). Decreased expres-
sion of E-cadherin in the progression of rat prostatic cancer. Cancer
Res 52, 2916–2922.
[23] Otto T, Rembrink K, Goepel M, Meyer-Schwickerath M, and Rubben H
(1993). E-cadherin: a marker for differentiation and invasiveness in
prostatic carcinoma. Urol Res 21, 359–362.
[24] Umbas R, Schalken JA, Aalders TW, Carter BS, Karthaus HF, Schaafsma
HE, Debruyne FM, and Isaacs WB (1992). Expression of the cellular
adhesionmolecule E-cadherin is reduced or absent in high-grade prostate
cancer. Cancer Res 52, 5104–5109.
[25] De Marzo AM, Knudsen B, Chan-Tack K, and Epstein JI (1999). E-
cadherin expression as a marker of tumor aggressiveness in routinely
processed radical prostatectomy specimens. Urology 53, 707–713.
[26] Rubin MA, Mucci NR, Figurski J, Fecko A, Pienta KJ, and Day ML
(2001). E-cadherin expression in prostate cancer: a broad survey
using high-density tissue microarray technology. Hum Pathol 32,
690–697.
[27] Guo Y, Sklar GN, Borkowski A, and Kyprianou N (1997). Loss of the
cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate
cancer correlates with tumor grade. Clin Cancer Res 3, 2269–2274.
[28] Cheville JC, Lloyd RV, Sebo TJ, Cheng L, Erickson L, Bostwick DG,
Lohse CM, and Wollan P (1998). Expression of p27kip1 in prostatic
adenocarcinoma. Mod Pathol 11, 324–328.
[29] Cordon-Cardo C, Koff A, Drobnjak M, Capodieci P, Osman I, Millard SS,
Gaudin PB, Fazzari M, Zhang ZF, Massague J, et al. (1998). Distinct
altered patterns of p27KIP1 gene expression in benign prostatic hyper-
plasia and prostatic carcinoma. J Natl Cancer Inst 90, 1284–1291.
[30] Tsihlias J, Kapusta LR, DeBoer G, Morava-Protzner I, Zbieranowski I,
Bhattacharya N, Catzavelos GC, Klotz LH, and Slingerland JM (1998).
66 Defining Aggressive Prostate Cancer Bismar et al.
Neoplasia . Vol. 8, No. 1, 2006
Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic
factor in localized human prostate adenocarcinoma. Cancer Res 58,
542–548.
[31] Yang RM, Naitoh J, Murphy M, Wang HJ, Phillipson J, deKernion JB,
Loda M, and Reiter RE (1998). Low p27 expression predicts poor
disease-free survival in patients with prostate cancer. J Urol 159,
941–945.
[32] Epstein JI, Carmichael M, and Partin AW (1995). OA-519 (fatty acid
synthase) as an independent predictor of pathologic state in adenocar-
cinoma of the prostate. Urology 45, 81–86.
[33] Shurbaji MS, Kalbfleisch JH, and Thurmond TS (1996). Immuno-
histochemical detection of a fatty acid synthase (OA-519) as a predictor
of progression of prostate cancer. Hum Pathol 27, 917–921.
[34] Swinnen JV, Roskams T, Joniau S, Van Poppel H, Oyen R, Baert L,
Heyns W, and Verhoeven G (2002). Overexpression of fatty acid syn-
thase is an early and common event in the development of prostate
cancer. Int J Cancer 98, 19–22.
[35] Baron A, Migita T, Tang D, and Loda M (2004). Fatty acid synthase: a
metabolic oncogene in prostate cancer? J Cell Biochem 91, 47–53.
[36] Bubendorf L, Sauter G, Moch H, Schmid HP, Gasser TC, Jordan P, and
Mihatsch MJ (1996). Ki67 labelling index: an independent predictor of
progression in prostate cancer treated by radical prostatectomy. J Pathol
178, 437–441.
[37] Botticelli AR, Casali AM, Botticelli L, and Zaffe D (1998). Immuno-
histochemical detection of cell-cycle associated markers on paraffin
embedded and formalin fixed needle biopsies of prostate cancer: cor-
relation of p120 protein expression with AgNOR, PCNA/cyclin, Ki-67/
MIB1 proliferation-scores and Gleason gradings. Eur J Histochem 42,
41–48.
[38] Bubendorf L, Tapia C, Gasser TC, Casella R, Grunder B, Moch H,
Mihatsch MJ, and Sauter G (1998). Ki67 labeling index in core needle
biopsies independently predicts tumor-specific survival in prostate can-
cer. Hum Pathol 29, 949–954.
[39] Gelmann EP (2002). Molecular biology of the androgen receptor. J Clin
Oncol 20, 3001–3015.
[40] Park C, Lee I, and Kang WK (2001). Lovastatin-induced E2F-1 modu-
lation and its effect on prostate cancer cell death. Carcinogenesis 22,
1727–1731.
[41] Farhana L, Dawson M, Rishi AK, Zhang Y, Van Buren E, Trivedi C,
Reichert U, Fang G, Kirschner MW, and Fontana JA (2002). Cyclin B
and E2F-1 expression in prostate carcinoma cells treated with the novel
retinoid CD437 are regulated by the ubiquitin-mediated pathway. Can-
cer Res 62, 3842–3849.
[42] Mu X and Chang C (2003). TR3 orphan nuclear receptor mediates
apoptosis through up-regulating E2F1 in human prostate cancer LNCaP
cells. J Biol Chem 278, 42840–42845.
[43] Foster CS, Falconer A, Dodson AR, Norman AR, Dennis N, Fletcher A,
Southgate C, Dowe A, Dearnaley D, Jhavar S, et al. (2004). Transcrip-
tion factor E2F3 overexpressed in prostate cancer independently pre-
dicts clinical outcome. Oncogene.
[44] Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, and Helin K
(2003). EZH2 is downstream of the pRB–E2F pathway, essential for
proliferation and amplified in cancer. EMBO J 22, 5323–5335.
[45] Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha
C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, et al. (2002).
The polycomb group protein EZH2 is involved in progression of pros-
tate cancer. Nature 419, 624–629.
[46] Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D,
Sewalt RG, Otte AP, Hayes DF, et al. (2003). EZH2 is a marker of
aggressive breast cancer and promotes neoplastic transformation of
breast epithelial cells. Proc Natl Acad Sci USA 100, 11606–11611.
[47] Martin DB, Gifford DR,Wright ME, Keller A, Yi E, Goodlett DR, Aebersold
R, and Nelson PS (2004). Quantitative proteomic analysis of proteins
released by neoplastic prostate epithelium. Cancer Res 64, 347–355.
[48] Santagata S, Demichelis F, Riva A, Varambally S, Hofer MD, Kutok JL,
Kim R, Tang J, Montie JE, Chinnaiyan AM, et al. (2004). JAGGED1
expression is associated with prostate cancer metastasis and recur-
rence. Cancer Res 64, 6854–6857.
[49] Hofer MD, Kuefer R, Varambally S, Li H, Ma J, Shapiro GI, Gschwend JE,
Hautmann RE, Sanda MG, Giehl K, et al. (2004). The role of metastasis-
associated protein 1 in prostate cancer progression. Cancer Res 64,
825–829.
[50] Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, Yang A,
Montironi R, McKeon F, and Loda M (2000). p63 is a prostate basal cell
marker and is required for prostate development. Am J Pathol 157,
1769–1775.
[51] Parsons JK, Gage WR, Nelson WG, and De Marzo AM (2001). p63
protein expression is rare in prostate adenocarcinoma: implications for
cancer diagnosis and carcinogenesis. Urology 58, 619–624.
[52] Davis LD, Zhang W, Merseburger A, Young D, Xu L, Rhim JS, Moul JW,
Srivastava S, and Sesterhenn IA (2002). p63 expression profile in
normal and malignant prostate epithelial cells. Anticancer Res 22,
3819–3825.
[53] Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K,
Ferrari M, Egevad L, Rayford W, Bergerheim U, et al. (2004). Gene
expression profiling identifies clinically relevant subtypes of prostate
cancer. Proc Natl Acad Sci USA 101, 811–816.
[54] Hale LP, Price DT, Sanchez LM, Demark-Wahnefried W, and Madden
JF (2001). Zinc alpha-2-glycoprotein is expressed by malignant pro-
static epithelium and may serve as a potential serum marker for pros-
tate cancer. Clin Cancer Res 7, 846–853.
[55] Kirschenbaum A, Itzkowitz SH, Wang JP, Yao S, Eliashvili M, and Levine
AC (1999). MUC1 expression in prostate carcinoma: correlation with
grade and stage. Mol Urol 3, 163–168.
[56] Nomura T, Mimata H, Takeuchi Y, Yamamoto H, Miyamoto E, and Nomura
Y (2003). The X-linked inhibitor of apoptosis protein inhibits Taxol-induced
apoptosis in LNCaP cells. Urol Res 31, 37–44.
[57] Ng CP and Bonavida B (2002). X-linked inhibitor of apoptosis (XIAP)
blocks Apo2 ligand/tumor necrosis factor – related apoptosis-inducing
ligand-mediated apoptosis of prostate cancer cells in the presence of
mitochondrial activation: sensitization by overexpression of second
mitochondria-derived activator of caspase/direct IAP-binding protein
with low pl (Smac/DIABLO). Mol Cancer Ther 1, 1051–1058.
[58] Cher ML, MacGrogan D, Bookstein R, Brown JA, Jenkins RB, and
Jensen RH (1994). Comparative genomic hybridization, allelic imbal-
ance, and fluorescence in situ hybridization on chromosome 8 in pros-
tate cancer. Genes Chromosomes Cancer 11, 153–162.
[59] Macoska JA, Trybus TM, and Wojno KJ (2000). 8p22 loss concurrent
with 8c gain is associated with poor outcome in prostate cancer. Urology
55, 776–782.
[60] Macoska JA, Trybus TM, Sakr WA, Wolf MC, Benson PD, Powell IJ,
and Pontes JE (1994). Fluorescence in situ hybridization analysis of 8p
allelic loss and chromosome 8 instability in human prostate cancer.
Cancer Res 54, 3824–3830.
[61] Macoska JA, Trybus TM, Benson PD, Sakr WA, Grignon DJ, Wojno KD,
Pietruk T, and Powell IJ (1995). Evidence for three tumor suppressor
gene loci on chromosome 8p in human prostate cancer. Cancer Res
55, 5390–5395.
[62] Macoska JA, Micale MA, Sakr WA, Benson PD, and Wolman SR
(1993). Extensive genetic alterations in prostate cancer revealed by
dual PCR and FISH analysis. Genes Chromosomes Cancer 8, 88–97.
[63] Wang R, Xu J, Saramaki O, Visakorpi T, Sutherland WM, Zhou J, Sen
B, Lim SD, Mabjeesh N, Amin M, et al. (2004). PrLZ, a novel prostate-
specific and androgen-responsive gene of the TPD52 family, is am-
plified in chromosome 8q21.1 and overexpressed in human prostate
cancer. Cancer Res 64, 1589–1594.
[64] Rubin MA, Varambally S, Beroukhim R, Tomlins SA, Rhodes DR, Paris
PL, Hofer MD, Storz-Schweizer M, Kuefer R, Fletcher JA, et al. (2004).
Overexpression, amplification, and androgen regulation of TPD52 in
prostate cancer. Cancer Res 64, 3814–3822.
[65] Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HF,
Oosterhof GO, Debruyne FM, and Schalken JA (1994). Decreased
E-cadherin expression is associated with poor prognosis in patients
with prostate cancer. Cancer Res 54, 3929–3933.
[66] Krajewska Maryla KS, Banares S, Huang X, Turner B, Bubendorf L,
Kallioniemi O-P, Shabaik A, Vitiello A, Peehl D, Gao G-J, et al. (2003).
Elevated expression of inhibitor of apoptosis proteins in prostate cancer.
Clin Cancer Res 9, 4914–4925.
[67] Narla G, Heath KE, Reeves HL, Li D, Giono LE, Kimmelman AC,
Glucksman MJ, Narla J, Eng FJ, Chan AM, et al. (2001). KLF6, a can-
didate tumor suppressor gene mutated in prostate cancer. Science
294, 2563–2566.
[68] Eisen MB, Spellman PT, Brown PO, and Botstein D (1998). Cluster
analysis and display of genome-wide expression patterns. Proc Natl
Acad Sci USA 95, 14863–14868.
[69] Li C and Wong WH (2001). Model-based analysis of oligonucleotide
arrays: expression index computation and outlier detection. Proc Natl
Acad Sci USA 98, 31–36.
[70] Jiang H, Deng Y, Chen HS, Tao L, Sha Q, Chen J, Tsai CJ, and Zhang
S (2004). Joint analysis of two microarray gene-expression data sets
to select lung adenocarcinoma marker genes. BMC Bioinformatics
5, 81.
[71] Johnson RA and Wichern DW (2002). Applied Multivariate Statistical
Analysis, 5th ed. Upper Saddle River, NJ: Prentice Hall; p. 767. (xviii).
Defining Aggressive Prostate Cancer Bismar et al. 67
Neoplasia . Vol. 8, No. 1, 2006
[72] Ihaka R and Gentleman R (1996). R: a language for data analysis and
graphics. J Comput Graph Stat 5, 299–314.
[73] Rubin MA and De Marzo AM (2004). Molecular genetics of human
prostate cancer. Mod Pathol 17, 380–388.
[74] DeMarzo AM, Nelson WG, Isaacs WB, and Epstein JI (2003). Patholog-
ical and molecular aspects of prostate cancer. Lancet 361, 955–964.
[75] Monti S, Savage KJ, Kutok JL, Feuerhake F, Kurtin P, Mihm M, Wu B,
Pasqualucci L, Neuberg D, Aguiar RC, et al. (2004). Molecular profiling
of diffuse large B-cell lymphoma identifies robust subtypes including
one characterized by host inflammatory response. Blood.
[76] Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J,
Puigserver P, Carlsson E, Ridderstrale M, Laurila E, et al. (2003). PGC-1
alpha–responsive genes involved in oxidative phosphorylation are coor-
dinately downregulated in human diabetes. Nat Genet 34, 267–273.
[77] Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette
MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. (2005).
From the cover: gene set enrichment analysis: a knowledge-based
approach for interpreting genome-wide expression profiles. Proc Natl
Acad Sci USA 102, 15545–15550.
[78] Glinsky GV, Berezovska O, and Glinskii AB (2005). Microarray analysis
identifies a death-from-cancer signature predicting therapy failure in
patients with multiple types of cancer. J Clin Invest 115, 1503–1521.
[79] Lessard J and Sauvageau G (2003). Bmi-1 determines the proli-
ferative capacity of normal and leukaemic stem cells. Nature 423,
255–260.
[80] Park IK, Qian D, Kiel M, Becker MW, Pihalja M, Weissman IL, Morrison
SJ, and Clarke MF (2003). Bmi-1 is required for maintenance of adult
self-renewing haematopoietic stem cells. Nature 423, 302–305.
68 Defining Aggressive Prostate Cancer Bismar et al.
Neoplasia . Vol. 8, No. 1, 2006
